Seaport Therapeutics (SPTX)
Develops lymphatic-targeted oral prodrugs for neuropsychiatric disorders.
$24.88
At close+1.27 (+5.38%)
Something off on this page? Send us feedback.
Next report
Nov 2, 2026
estimated · in 60 days
EPS estimate
−$0.58
Revenue estimate
—
Fiscal quarter
Q3 FY26
EPSReportedEstimate
——————Aug '26Nov '26
Reported——————−$1.78Pending
Estimate——————−$0.62−$0.58
Surprise——————−186.9%—
RevenueReportedEstimate
——————Aug '26Nov '26
Reported———————Pending
Estimate————————
Surprise————————
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.58 | — | — |
| Aug 2026 | −$0.62 | −$1.78 | −186.9% |
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | −$0.58 | — | — | — | — | — | — |
| Aug 3, 2026 | −$0.62 | −$1.78 | −186.9% | — | — | — | +0.9% |